BLRX · Bioline Rx Ltd ADR
United States · RS rating 12 · As of 2026-10-14
| Price | 2.08 USD |
|---|---|
| 1-day change | -4.4% |
| RS rating (overall / 1M / 3M / 12M) | 12 / 13 / 12 / 15 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 16 / 17 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -54.6% |
| Distance from 52-week high | +48.4% |
| Market cap (USD) | $10.3M |